Why Investors Should Resist Buying Karuna Therapeutics, Even Though It's Surging
One biotech stock making recent headlines is Karuna Therapeutics (NASDAQ: KRTX). This company, now with a market capitalization of $2.9 billion, has seen its shares skyrocket by over 700% since announcing impressive results for its schizophrenia drug candidate.
It's definitely a big win for both the company and its shareholders, but investors thinking about making Karuna a part of their portfolio in light of this news shouldn't be too hasty. There are a few things worth mentioning before you consider buying shares in this hot stock.
Image source: Getty Images.
Source Fool.com
